Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT05201456

LithoVue Elite Registry

LithoVue Elite (LVE) Registry

Status
Withdrawn
Phase
Study type
Observational
Enrollment
0 (actual)
Sponsor
Boston Scientific Corporation · Industry
Sex
All
Age
Healthy volunteers
Not accepted

Summary

To obtain postmarket safety and efficacy data on Boston Scientific LithoVue™ Elite System.

Detailed description

LithoVue Elite Registry is a post-market, multi-center, open label, non-randomized, prospective study to document the safety and efficacy data on Boston Scientific LithoVue™ Elite System. LithoVue Elite System, includes the StoneSmart™ Connect Console (reusable capital/workstation) and a single-use, disposable ureteroscope device. The LithoVue Elite System is intended to be used to visualize organs, cavities and canals in the urinary tract (urethra, bladder, ureter, calyces and renal papillae) via transurethral or percutaneous access routes. It can also be used in conjunction with endoscopic accessories to perform various diagnostic and therapeutic procedures in the urinary tract. This is a post-market registry study. Any subject who meets eligibility criteria, intends to undergo a diagnostic and/or therapeutic procedure utilizing the LithoVue Elite System, and is willing to provide written informed consent, will be approached and considered for enrollment in the study. Data from diagnostic/therapeutic ureteroscopy procedure and standard of care post-ureteroscopy follow-up visits will be collected. These standard of care follow-up visits are expected to be scheduled within 120 days of the ureteroscopic procedure.

Conditions

Interventions

TypeNameDescription
DEVICELithoVue Elite SystemThe LithoVue Elite System is intended to be used to visualize organs, cavities and canals in the urinary tract (urethra, bladder, ureter, calyces and renal papillae) via transurethral or percutaneous access routes. It can also be used in conjunction with endoscopic accessories to perform various diagnostic and therapeutic procedures in the urinary tract.

Timeline

Start date
2023-04-01
Primary completion
2023-04-01
Completion
2023-12-01
First posted
2022-01-21
Last updated
2023-12-18

Regulatory

Source: ClinicalTrials.gov record NCT05201456. Inclusion in this directory is not an endorsement.